vs
IONIS PHARMACEUTICALS INC（IONS）与Riley Exploration Permian, Inc.（REPX）财务数据对比。点击上方公司名可切换其他公司
IONIS PHARMACEUTICALS INC的季度营收约是Riley Exploration Permian, Inc.的1.8倍（$203.3M vs $113.9M），Riley Exploration Permian, Inc.净利率更高（-61.8% vs -112.8%，领先51.0%），Riley Exploration Permian, Inc.同比增速更快（11.2% vs -10.3%），Riley Exploration Permian, Inc.自由现金流更多（$24.6M vs $-159.0M），过去两年IONIS PHARMACEUTICALS INC的营收复合增速更高（30.4% vs 3.9%）
IONIS制药是1989年成立的生物科技企业，总部位于美国加利福尼亚州卡尔斯巴德，专注于反义疗法、RNA干扰及CRISPR疗法的研发，2015年12月前曾以Isis制药的名称运营。
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
IONS vs REPX — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $203.3M | $113.9M |
| 净利润 | $-229.4M | $-70.4M |
| 毛利率 | 96.1% | — |
| 营业利润率 | -105.5% | 38.3% |
| 净利率 | -112.8% | -61.8% |
| 营收同比 | -10.3% | 11.2% |
| 净利润同比 | -119.8% | — |
| 每股收益（稀释后） | $-1.35 | $-3.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $113.9M | ||
| Q4 25 | $203.3M | $97.3M | ||
| Q3 25 | $156.7M | $106.9M | ||
| Q2 25 | $452.0M | $85.4M | ||
| Q1 25 | $131.6M | $102.5M | ||
| Q4 24 | $226.6M | $102.7M | ||
| Q3 24 | $133.8M | $102.3M | ||
| Q2 24 | $225.3M | $105.4M |
| Q1 26 | — | $-70.4M | ||
| Q4 25 | $-229.4M | — | ||
| Q3 25 | $-128.6M | $16.3M | ||
| Q2 25 | $123.6M | $30.5M | ||
| Q1 25 | $-146.9M | $28.6M | ||
| Q4 24 | $-104.3M | — | ||
| Q3 24 | $-140.5M | $25.7M | ||
| Q2 24 | $-66.3M | $33.5M |
| Q1 26 | — | — | ||
| Q4 25 | 96.1% | — | ||
| Q3 25 | 98.5% | — | ||
| Q2 25 | 99.1% | — | ||
| Q1 25 | 98.9% | — | ||
| Q4 24 | 98.3% | — | ||
| Q3 24 | 99.2% | — | ||
| Q2 24 | 98.2% | — |
| Q1 26 | — | 38.3% | ||
| Q4 25 | -105.5% | 26.9% | ||
| Q3 25 | -102.2% | 27.0% | ||
| Q2 25 | 30.9% | 33.7% | ||
| Q1 25 | -111.6% | 48.3% | ||
| Q4 24 | -48.9% | 31.2% | ||
| Q3 24 | -111.1% | 17.1% | ||
| Q2 24 | -29.3% | 50.9% |
| Q1 26 | — | -61.8% | ||
| Q4 25 | -112.8% | — | ||
| Q3 25 | -82.1% | 15.3% | ||
| Q2 25 | 27.3% | 35.7% | ||
| Q1 25 | -111.6% | 27.9% | ||
| Q4 24 | -46.1% | — | ||
| Q3 24 | -105.0% | 25.1% | ||
| Q2 24 | -29.4% | 31.8% |
| Q1 26 | — | $-3.38 | ||
| Q4 25 | $-1.35 | $4.02 | ||
| Q3 25 | $-0.80 | $0.77 | ||
| Q2 25 | $0.70 | $1.44 | ||
| Q1 25 | $-0.93 | $1.36 | ||
| Q4 24 | $-0.66 | $0.52 | ||
| Q3 24 | $-0.95 | $1.21 | ||
| Q2 24 | $-0.45 | $1.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.7B | — |
| 总债务越低越好 | $1.8B | $240.7M |
| 股东权益账面价值 | $489.1M | $553.4M |
| 总资产 | $3.5B | $1.2B |
| 负债/权益比越低杠杆越低 | 3.71× | 0.43× |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | — | $240.7M | ||
| Q4 25 | $1.8B | $247.9M | ||
| Q3 25 | — | $367.0M | ||
| Q2 25 | — | $275.2M | ||
| Q1 25 | — | $249.3M | ||
| Q4 24 | $1.3B | $269.5M | ||
| Q3 24 | — | $288.6M | ||
| Q2 24 | — | $322.7M |
| Q1 26 | — | $553.4M | ||
| Q4 25 | $489.1M | $634.2M | ||
| Q3 25 | $618.0M | $566.5M | ||
| Q2 25 | $631.7M | $556.9M | ||
| Q1 25 | $475.7M | $532.4M | ||
| Q4 24 | $588.4M | $510.6M | ||
| Q3 24 | $662.5M | $507.4M | ||
| Q2 24 | $263.7M | $489.0M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $3.5B | $1.2B | ||
| Q3 25 | $3.0B | $1.2B | ||
| Q2 25 | $3.0B | $1.0B | ||
| Q1 25 | $2.8B | $994.9M | ||
| Q4 24 | $3.0B | $993.5M | ||
| Q3 24 | $3.1B | $997.9M | ||
| Q2 24 | $2.7B | $1.0B |
| Q1 26 | — | 0.43× | ||
| Q4 25 | 3.71× | 0.39× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | 2.13× | 0.53× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.66× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-137.7M | $47.2M |
| 自由现金流经营现金流 - 资本支出 | $-159.0M | $24.6M |
| 自由现金流率自由现金流/营收 | -78.2% | 21.6% |
| 资本支出强度资本支出/营收 | 10.5% | 41.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-320.0M | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $47.2M | ||
| Q4 25 | $-137.7M | $64.9M | ||
| Q3 25 | $-131.4M | $63.6M | ||
| Q2 25 | $151.3M | $33.6M | ||
| Q1 25 | $-150.8M | $50.4M | ||
| Q4 24 | $-116.1M | $66.4M | ||
| Q3 24 | $-115.0M | $72.1M | ||
| Q2 24 | $-119.9M | $51.6M |
| Q1 26 | — | $24.6M | ||
| Q4 25 | $-159.0M | — | ||
| Q3 25 | $-136.7M | — | ||
| Q2 25 | $139.0M | — | ||
| Q1 25 | $-163.4M | — | ||
| Q4 24 | $-141.6M | — | ||
| Q3 24 | $-124.0M | — | ||
| Q2 24 | $-126.1M | — |
| Q1 26 | — | 21.6% | ||
| Q4 25 | -78.2% | — | ||
| Q3 25 | -87.2% | — | ||
| Q2 25 | 30.8% | — | ||
| Q1 25 | -124.1% | — | ||
| Q4 24 | -62.5% | — | ||
| Q3 24 | -92.7% | — | ||
| Q2 24 | -56.0% | — |
| Q1 26 | — | 41.3% | ||
| Q4 25 | 10.5% | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 11.3% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 2.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 3.90× | ||
| Q2 25 | 1.22× | 1.10× | ||
| Q1 25 | — | 1.76× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 1.54× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IONS
| Products | $58.0M | 29% |
| Spinraza Royalties | $54.0M | 27% |
| Collaborative Agreement Revenue | $52.4M | 26% |
| Wainus Royalties | $16.0M | 8% |
| Wainua Joint Development Revenue | $9.6M | 5% |
| Other Commercial | $7.6M | 4% |
| Other Royalties | $5.7M | 3% |
REPX
暂无分部数据
